Why the study?
Neuroleptic malignant syndrome is conventionally associated with first-generation antipsychotics, but it has also been described with atypical antipsychotics including ziprasidone.
Answers are grounded in this paper and cite their sources.
Ziprasidone, an atypical antipsychotic, can induce potentially fatal neuroleptic malignant syndrome even at therapeutic doses.
Neuroleptic malignant syndrome (NMS) is a well-recognized neurologic emergency. It presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes. The syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift. NMS is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including Ziprasidone. A case of NMS with Ziprasidone use at the therapeutic dose is reported here.
No takes yet. Share an insight, caveat, or question.
Sedhai et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: